Yttrium-90 Radioembolization Matures Into a Full Service Line, Not Just a Procedure

Yttrium-90 radioembolization, once considered a salvage option for patients who had run out of alternatives, has quietly become one of the most versatile weapons in the fight against liver cancer. A new review published in CVIR Oncology argues that the therapy’s clinical evolution is now only half the story: the real challenge for hospitals is whether they can deliver it safely, consistently, and in alignment with multidisciplinary care goals. The authors, led by Christopher Malone of WashU Medicine’s Mallinckrodt Institute of Radiology, lay out a practical blueprint for building what they call a high-performing radioembolization program, and their message is blunt. Technical capability alone does not make a program succeed.

The clinical rationale for expanding access is grounded in shifting epidemiology. Hepatocellular carcinoma, the most common primary liver cancer, has risen substantially in incidence and mortality in the United States and worldwide, increasingly driven by non-viral causes such as metabolic-dysfunction-associated steatotic liver disease, or MASLD. Current American Association for the Study of Liver Diseases guidelines do not recommend routine surveillance for most MASLD patients unless they develop cirrhosis, which means many tumors are caught at later stages. With roughly two-thirds of patients falling into the intermediate or advanced categories of the Barcelona Clinic Liver Cancer staging system, where liver-directed therapies play a central and evolving role, the authors contend that improved access to these treatments is essential to meet a growing healthcare burden.

Radioembolization works by threading millions of microscopic beads loaded with yttrium-90, a beta-emitting radionuclide, through the hepatic artery directly into the vessels feeding a tumor. The radiation travels an average of only a few millimeters in tissue, delivering tumoricidal doses while sparing much of the surrounding liver. Over the past two decades the technique has moved from lobar, body-surface-area-based dosing toward superselective, segmental delivery guided by personalized dosimetry. That shift has transformed its role. Radiation segmentectomy, in which an ablative dose is concentrated in one or two liver segments, has created a curative-intent option for selected patients with early-stage disease who are not ideal candidates for surgery or thermal ablation.

The evidence supporting this evolution is now substantial. Early randomized trials comparing radioembolization with the drug sorafenib, including SARAH and SIRveNIB, showed no overall survival advantage, but those studies predate modern patient selection and dosimetry. A post hoc analysis of SARAH found that patients receiving adequate tumor absorbed dose derived greater benefit, pointing directly at dosimetry as the missing variable. The randomized DOSISPHERE-01 trial then demonstrated improved objective response rates and overall survival when dosing was personalized to maximize tumor absorbed dose compared with standard approaches. Studies such as LEGACY, RASER, and DOORwaY90 have since shown high response rates with segmental high-dose delivery, and comparative trials including TRACE and PREMIERE suggest potential advantages over chemoembolization in selected patients, including longer time to progression and fewer treatment sessions.

In the transplant arena, radioembolization has become the most commonly used liver-directed therapy in the United States for bridging and downstaging patients awaiting a new liver. A key metric is complete pathologic necrosis, the disappearance of viable tumor on examination of the explanted liver, which radioembolization achieves at consistently high rates compared with other locoregional therapies and which is associated with better post-transplant outcomes. Emerging data suggest, however, that factors beyond mean tumor dose, such as microsphere-specific activity, particle density, and spatial dose heterogeneity, may independently influence the radiobiologic effect. Because glass and resin microspheres differ substantially in these properties, the authors caution that dose targets and delivery strategies may not be interchangeable across platforms, and future guidelines should account for microsphere type, treated vascular territory, and the intended biologic endpoint.

Regulatory milestones have accelerated adoption. The U.S. Food and Drug Administration granted premarket approval for TheraSphere glass microspheres for unresectable hepatocellular carcinoma in March 2021, while SIR-Spheres resin microspheres, approved in 2002 for colorectal liver metastases, received an added unresectable HCC indication in 2025. Unified practice parameters, including the 2023 ACR-ABS-ACNM-ARS-SIR-SNMMI practice parameter, have standardized patient selection, lung shunt assessment, dose planning, and radiation safety, making results more reproducible across centers. But standardization also raises the bar: a credible program now requires reliable nuclear medicine collaboration, dosimetry support, trained interventional radiology staff, consistent imaging protocols, and a system for tracking outcomes.

The operational heart of the review is a detailed team structure. Interventional radiologists lead protocol development, case selection, dosimetry oversight, and informed consent, supported by nurses, technologists, and advanced practice providers. Medical physicists implement and audit dosimetric protocols; nuclear medicine physicians and radiopharmacists manage the radiotracer and interpret lung shunt and post-therapy imaging; and hepatology, oncology, transplant surgery, diagnostic radiology, and palliative care contribute through a multidisciplinary tumor board. A standardized pathway converts this structure into reproducible care, moving patients from referral intake through tumor board presentation, interventional radiology clinic visits, mapping angiography with technetium-99m MAA imaging, dosimetric review, treatment, and structured follow-up. Quality is monitored with pragmatic metrics: process measures such as time from referral to treatment and a work-up completion rate above 90 percent as an aspirational benchmark, clinical measures such as response rates and downstaging success, and safety measures tracking unplanned admissions, gastrointestinal ulceration, radiation pneumonitis, and deterioration in liver function within 90 days.

A recurring theme is the central role of the dedicated nurse coordinator, who serves as the program’s operational and clinical liaison. Within the boundaries of nursing scope of practice, the coordinator navigates patients through the pathway, prepares families for the logistics of separate mapping and treatment visits, coordinates authorizations and appointments across services, and conducts structured post-procedure check-ins to catch symptoms early. The authors emphasize that this role often becomes the most continuous point of contact for patients and families, providing emotional support and a trusted space for questions throughout a protracted treatment journey. Patient decision aids, including bilingual tools developed by the Interventional Initiative, have been shown in clinical trials to improve understanding and satisfaction before informed consent conversations.

The review also confronts the business case frankly. Hospitals that refer radioembolization cases out lose revenue from the entire episode of care, including imaging, clinic visits, mapping procedures, nuclear medicine studies, and follow-up. A make-versus-buy analysis must weigh fixed assets such as angiography suites and dosimetry software against variable costs and projected volume; a program may be profitable per case yet unjustifiable at very low volume near a high-quality regional center. Conversely, rural or geographically isolated hospitals may justify an in-house program even at lower volume if local treatment reduces travel burden and shortens time to therapy, considerations that carry particular weight for nonprofit and government systems. The authors propose a three-phase implementation timeline: stakeholder engagement, protocol development, and device-specific training; treatment of an initial cohort of straightforward cases with real-time dashboards tracking patient flow; and early outcomes review culminating in an internal playbook that consolidates workflows and supports onboarding and growth.

Ultimately, the authors argue that a high-performing radioembolization practice is best understood as a service line rather than a procedure. Durable, reproducible outcomes require an intentional infrastructure linking multidisciplinary decision-making, evidence-based selection, personalized dosimetry, nuclear medicine partnership, trained procedural teams, coordinated nursing navigation, and longitudinal outcome tracking. When leadership support, patient-centered education, and continuous process improvement are deliberately built in, the therapy can expand access to advanced liver-directed treatment, reduce fragmentation of care, and strengthen the broader hepatobiliary oncology ecosystem. The future of radioembolization, they conclude, depends not only on better devices, dosimetry, and trials, but on building systems capable of delivering the therapy safely, consistently, and in alignment with patient goals.

Subject of Research: Building and sustaining high-performing yttrium-90 radioembolization programs for liver cancer

Article Title: Building a high-performing yttrium-90 radioembolization practice: from evidence to experience

Article References: Malone, C., Friend, C., Schmitt, B., Siskin, G., & Newton, I. (2026). Building a high-performing yttrium-90 radioembolization practice: from evidence to experience. CVIR Oncology, 2(1), Article 30. https://doi.org/10.1007/s44343-026-00064-0

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00064-0

Keywords: yttrium-90, radioembolization, hepatocellular carcinoma, radiation segmentectomy, personalized dosimetry, liver-directed therapy, interventional radiology, nuclear medicine, transplant bridging, multidisciplinary care, nurse coordinator, program development